---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-25-000018"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:42:17.972598+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Entrada receives UK authorization for Phase 1/2 trial of ENTR-601-45 in DMD exon 45 skipping

## Summary
- UK MHRA and Research Ethics Committee clearance to start ELEVATE-45-201, a Phase 1/2 MAD study of ENTR-601-45.
- On track to initiate the trial in Q3 2025; Part A will evaluate doses 5–15 mg/kg every 6 weeks in ~24 patients.
- Second Duchenne program (after ELEVATE-44); regulatory filings also submitted in the EU with review ongoing.
- Study is randomized, double-blind, placebo-controlled with a Part B for optimal dose evaluation and an OLE.
- CEO states strategy to run UK/EU studies first, then share data with FDA to enable U.S. registrational studies.

## SEC filing metadata
- accession: 0001689375-25-000018
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01, 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937525000018/0001689375-25-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937525000018/trda-20250324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-25-000018
- JSON: https://secwatch.observer/filing/0001689375-25-000018.json
- Plain text: https://secwatch.observer/filing/0001689375-25-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.